1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,400 | 5,850 | 20.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Cantor Fitzgerald reiterates Overweight rating on Eupraxia stock at $11 | 1 | Investing.com | ||
| 14.11. | Eupraxia: Cantor Fitzgerald bestätigt "Overweight"-Rating und sieht 73 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 13.11. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI | 181 | GlobeNewswire (Europe) | The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus... ► Artikel lesen | |
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.11. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals ends Q3 with cash of $89M | 1 | Stockwatch | ||
| 04.11. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results | 52 | GlobeNewswire (Europe) | Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by... ► Artikel lesen | |
| 04.11. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10. | This analyst loves Eupraxia Pharmaceuticals | 1 | Cantech Letter | ||
| 02.10. | H.C. Wainwright bestätigt Kaufempfehlung für Eupraxia nach starken Studiendaten | 1 | Investing.com Deutsch | ||
| 02.10. | H.C. Wainwright reiterates Buy rating on Eupraxia Pharmaceuticals stock | 1 | Investing.com | ||
| 30.09. | Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study | 1 | Benzinga.com | ||
| 30.09. | Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald | 3 | Investing.com | ||
| 29.09. | Eupraxia reports positive data from highest dose cohort in EoE trial | 1 | Investing.com | ||
| 29.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs | 492 | GlobeNewswire (Europe) | Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients... ► Artikel lesen | |
| 29.09. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 25.09. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals closes $80.5-million offering | 1 | Stockwatch | ||
| 24.09. | Eupraxia Pharmaceuticals schließt Kapitalerhöhung über 80,5 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 24.09. | Eupraxia pharmaceuticals raises $80.5 million in public offering | 2 | Investing.com | ||
| 24.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option | 358 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 23.09. | Eupraxia Pharmaceuticals: Aktie fällt nach Platzierung einer 70-Millionen-Dollar-Kapitalerhöhung | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,52 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| IMMUNEERING | 5,650 | -0,35 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,400 | +3,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 4,360 | -3,11 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | -2,87 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | -3,05 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | +3,55 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
Das Unternehmen EUPRAXIA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,98 % bei einem Aktienkurs von 5,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.